Renal protection CT protocol using low-dose and low-concentration iodine contrast medium in at-risk patients of HCC and with chronic kidney disease: a randomized controlled non-inferiority trial.

"Declarations Ethics approval and consent to participateThis prospective study was approved by the institutional review board of Seoul National University Hospital (IRB No: H-1902-023-1008). Written informed consent was obtained in all participants. Consent for publicationNot applicable. Competing interestsJeong Hee Yoon: Honoraria from Accuzen, Bayer and Philips Healthcare. Consulting fee from Bayer. Jeong Min Lee: Grant from Bayer, Bracco, Canon, Central Medical Servis, Dongkuk Pharma, GE Healthcare, Guerbet, Philips Healthcare, Samsung Medison, Siemens Healthineers; Consulting fees from Sansumg medison; Honoraria from Bayer, Claripi, GE Healthcare, Guerbet, Philips Healthcare, Samsung Medison, Siemens Healthineers. Other authors (J.Y.P., S.M.L., E.S.L., J.H.K.) declared no competing interests. Competing interests Jeong Hee Yoon: Honoraria from Accuzen, Bayer and Philips Healthcare. Consulting fee from Bayer. Jeong Min Lee: Grant from Bayer, Bracco, Canon, Central Medical Servis, Dongkuk Pharma, GE Healthcare, Guerbet, Philips Healthcare, Samsung Medison, Siemens Healthineers; Consulting fees from Sansumg medison; Honoraria from Bayer, Claripi, GE Healthcare, Guerbet, Philips Healthcare, Samsung Medison, Siemens Healthineers. Other authors (J.Y.P., S.M.L., E.S.L., J.H.K.) declared no competing interests."

"Funding This study was funded by Riyeon Pharmaceuticals (Seoul, Republic of Korea, grant No 1902-023-1008)."

"Trial registration clinicaltrials.gov, NCT04024514, Registered July 18, 2019, prospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT04024514."